Filing Flows › TScan Therapeutics (TCRX) › Q1 2026
TScan Therapeutics (TCRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
TScan Therapeutics (TCRX) reported revenue of $982K for the first quarter 2026 (Q1 2026), -55% from a year earlier and -62% from the quarter before.
TScan Therapeutics, Q1 2026: revenue $982K (-55% year over year), net loss $28.7M, operating cash flow −$24.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $982K | -62% | -55% |
| Operating profit | −$29.1M | — | — |
| Net earnings | −$28.7M | — | — |
| Operating cash flow | −$24.3M | — | — |
What changed
Revenue was $1.0M in Q1 2026, down 55% year over year and down 62% from the previous quarter.
Operating costs exceeded revenue by $29.1M, an operating margin of -2967.3%. Total costs fell 22% while revenue fell 55%. The quarter ended with a net loss of $28.7M, wider than the previous quarter's $23.0M loss.
Operating cash flow was −$24.3M. Non-cash charges added back $693K of depreciation and $2.5M of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $70K exceeded it, leaving free cash flow of −$24.3M.
Questions
What was TScan Therapeutics' revenue in the first quarter 2026?
TScan Therapeutics (TCRX) reported revenue of $982K for the first quarter 2026 (Q1 2026), -55% from a year earlier and -62% from the quarter before.
Source: TScan Therapeutics 10-Q on SEC EDGAR.